New hope for tough-to-treat stroke? tirofiban tested in 516 patients

NCT ID NCT06037889

Completed Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a powerful blood thinner called tirofiban can improve recovery in people with a specific type of stroke called branch atheromatous disease (BAD). BAD strokes often get worse quickly and have few good treatments. The trial enrolled 516 adults within 48 hours of stroke onset. Half received tirofiban plus standard care, and half received standard care alone. The main goal was to see if more people in the tirofiban group could return to near-normal function (no or minimal disability) after 90 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Tirofiban (a blood-thinning drug given through a vein)

What this could lead to

If it works, this could offer a more effective treatment for a type of stroke that often leads to rapid worsening and poor recovery.

What could go wrong

This is a completed Phase 3 trial, but results are not yet published. Tirofiban increases bleeding risk, which could outweigh benefits. The benefit may be small or not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRANCH ATHEROMATOUS DISEASE

Contacts and locations

Show contact details

Locations

Affiliated Hospital of Chifeng University

Chifeng, Hebei, 024099, China
Beijing Shijitan Hospital, Capital Medical University

Beijing, Beijing Municipality, China
Beijing Shunyi Hospital

Beijing, Beijing Municipality, 101300, China
Botou City Hospital

Botou, Hebei, China
Cangzhou Central Hospital

Cangzhou, Hebei, China
Chengde Central Hospital

Chengde, Hebei, 067024, China
Deyang People's Hospital

Deyang, Sichuan, 618099, China
Hengshui People's Hospital

Hengshui, Hebei, 053099, China
Jinan Central Hospital

Jinan, Shandong, 250013, China
Meihekou Central Hospital

Meihekou, Jilin, 135022, China
Mianyang Central Hospital

Mianyang, Sichuan, 621099, China
North China University of Science and Technology Affiliated Hospital

Tangshan, Hebei, 063000, China
Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China
Shengli Oilfield Central Hospital

Dongying, Shandong, 257099, China
The First Affiliated Hospital of Xinxiang Medical Unversity

Xinxiang, Henan, 453100, China
The First Hospital of Tsinghua University

Beijing, Beijing Municipality, China
The First People's Hospital of Shangqiu

Shangqiu, Henan, 476005, China
The First People's Hospital of Yibin

Yibin, Sichuan, 644000, China
The Second Affiliated Hospital of Harbin Medical University

Harbin, Heilongjiang, 150001, China
The Second Hospital of Tianjin Medical University

Tianjing, Tianjing, 300211, China
The Second People's Hospital of Yibin

Yibin, Sichuan, 644000, China
The second hospital of Baoding

Baoding, Hebei, 071051, China
Tibet Autonomous Region People's Hospital

Lhasa, Tibet, 850000, China
Xuzhou Central Hospital

Xuzhou, Jiangsu, 221009, China
Yellow River SANMENXIA Hospital

Sanmenxia, Henan, China